Antimicrobials · Antifungals
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Voriconazole is the first-line treatment for invasive aspergillosis.
Patients treated with voriconazole frequently experience transient visual disturbances, including blurred vision and photopsia.
Long-term use of voriconazole is associated with an increased risk of phototoxicity and squamous cell carcinoma of the skin.
Voriconazole is a potent CYP450 inhibitor, leading to significant drug-drug interactions with medications like warfarin and cyclosporine.
The drug is contraindicated in patients with severe renal impairment when administered intravenously due to the accumulation of the cyclodextrin vehicle.
Voriconazole can cause QT interval prolongation, necessitating baseline and periodic ECG monitoring.
Therapeutic drug level monitoring is required to ensure efficacy and prevent neurotoxicity, which manifests as hallucinations or confusion.
Vignette unlocked
A 54-year-old male with acute myeloid leukemia currently undergoing induction chemotherapy presents with a persistent fever and cough. A CT scan of the chest reveals a halo sign surrounding a pulmonary nodule. He is started on an intravenous antifungal agent. Two days later, he reports that his vision seems 'bright' and 'shimmering' whenever he enters a well-lit room. Physical examination reveals no focal neurological deficits, and his QTc interval is slightly prolonged on ECG.
Which of the following medications is the most likely cause of this patient's visual symptoms?
Voriconazole
The patient's clinical presentation of invasive aspergillosis (halo sign) treated with voriconazole is classic for the drug's hallmark side effect of transient visual disturbances (photopsia).
Full handout
High yield triage
Classification
Second-generation triazole antifungal.
Indications
Invasive aspergillosis (first-line).
Mechanism of Action
Inhibits 14-alpha-lanosterol demethylase to block ergosterol synthesis.
Side Effects
Visual disturbances, hepatotoxicity, QT prolongation.
Contraindications / Monitoring
CYP3A4 inhibitors; monitor trough levels and LFTs.
Full handout
Mechanism of Action
Voriconazole binds to the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase. This inhibition prevents the conversion of lanosterol to ergosterol, a vital component of the fungal cell membrane. The resulting depletion of ergosterol leads to membrane instability and fungal cell death. It is highly effective against Aspergillus species and Candida.
Unique Properties
Unlike fluconazole, voriconazole provides essential coverage for invasive aspergillosis. It exhibits non-linear, dose-dependent pharmacokinetics, making it prone to unpredictable serum concentrations. It is the gold standard for primary treatment of invasive mold infections.
Indications
It is the first-line treatment for invasive aspergillosis. It is also utilized for salvage therapy in esophageal candidiasis and infections caused by Scedosporium or Fusarium. It is not indicated for Cryptococcus infections.
Pharmacokinetics
Metabolized extensively by the hepatic CYP450 system (2C19, 2C9, 3A4). Genetic polymorphism of CYP2C19 significantly impacts drug clearance, necessitating therapeutic drug monitoring. It is a potent inhibitor of CYP3A4, leading to numerous drug-drug interactions.
Side Effects & Adverse Events
Transient visual disturbances (photopsia, color changes) occur in up to 30% of patients. Hepatotoxicity is common, requiring baseline and periodic LFT monitoring. QT prolongation increases the risk of torsades de pointes. Long-term use is associated with phototoxicity and increased risk of squamous cell carcinoma.
Contraindications
Co-administration with CYP3A4 inducers (e.g., rifampin, carbamazepine) is contraindicated due to subtherapeutic levels. Hypersensitivity to azoles is an absolute contraindication. Use with caution in patients with pre-existing hepatic impairment.
Monitoring
Perform therapeutic drug monitoring (TDM) to maintain trough levels between 1-5.5 mcg/mL. Monitor LFTs (ALT/AST/Bilirubin) at baseline and weekly during therapy. Obtain an ECG to assess the QTc interval in patients with cardiac risk factors.
Clinical Pearls
Always suspect voriconazole if a patient on antifungal therapy reports hallucinations or visual flashes. Remember the board-favorite association: Voriconazole + long-term use = skin cancer. It is the drug of choice for Aspergillus, whereas fluconazole is the drug of choice for Candida.